Social Pharmacy and Pharmacovigilance - PowerPoint Presentation

Slide1

Social Pharmacy and Pharmacovigilance

JAMASOFT2017

1Slide2

Social PharmacyPharmacoepidemiology

Pharmacovigilance

JAMASOFT2017

2Slide3

Parmacovigilance system collects data throughout the

lifecycle

of each

medicinal

product

.

This system helps to continually evaluate and maintain

product safety

.

JAMASOFT2017

3Slide4

What is pharmacovigilance?The word pharmacovigilance is derived from the Greek ‘Pharmaco’ (medicine) and the Latin ‘

Vigilantia’ (vigilance, watchfulness).

It is the process of monitoring, evaluating and improving the safety of medicines in use.

It is carried out by pharmaceutical companies on their products and by government agencies on all medicinal products.

JAMASOFT2017

4Slide5

„Pharmacovigilanceis the

science

and activities

relating to the detection, assessment, understanding and prevention of adverse effects

or any other medicine-related problem

„

-

As defined by WHO

.

JAMASOFT2017

5Slide6

Pharmacovigilance is to be seen as

the process

of

collecting,

monitoring,

researching and

evaluating information

from healthcare providers and patients

for the purposes of understanding and preventing

drug-related problems

.

JAMASOFT2017

6Slide7

Physicians and, perhaps more particularly, governments

have long been more concerned with the safety of drugs than with their efficacy.

Hippocrates' principle of 'first not to harm

'

is widely remembered and it would be easy to find in the historical textbooks on pharmacy a number of regulatory measures taken even in ancient times in the hope of protecting people against

iatrogenic hazards

due to chemicals.

Indeed, whatever doubts that could reasonably hang over the genuine benefits of medicines in antiquity, their toxic nature was clear for many: in ancient Greek, the word

pharmakon

referred not only to medicines and drugs but also to poisons.

JAMASOFT2017

7Slide8

The Purpose of Pharmacovigilance.

The main purpose of pharmacovigilance is to improve the patient's safety and enhance his care in terms of the use of medicines, including paramedical interventions.

Pharmacovigilance also supports public health programs by providing reliable information for the efficient assessment of the risk-benefit profile of medicines.

Contribute to the assessment of benefits, uses, side effects, harm, effectiveness and risk of medicines.

Encouraging the safe, rational and more effective (including cost-effective) use of various medicines.

Promote education, understanding and clinical training in pharmacovigilance and its effective availability to the public.

JAMASOFT2017

8Slide9

What is a side effect?

This is an unwanted response to a medicine.

It may rarely be a positive experience but it is usually negative.

It may manifest as symptoms (e.g. headache, nausea) or as an illness (liver or kidney problems).

Doctors and pharmacists call these ‘adverse drug reactions’ or ‘adverse reactions’.

JAMASOFT2017

9Slide10

How common are side effects?Adverse reactions can occur with any medicine.

Adverse r

eactions related to the administration of the medicine are clearly listed in the information to prescribers (the

Summary of Product Characteristics

(

SPC

)) and in the package leaflet available to the patient.

JAMASOFT2017

10Slide11

Side effects can vary from patient to patient.

Many patients will get no side effects whatsoever. Even when they do happen, in most situations the benefit of the medicine to that individual patient can still maintain a positive balance.

If side effects become troublesome, however, you must promptly inform the doctor or pharmacist who looks after your medical care.

JAMASOFT2017

11Slide12

What is a serious adverse reaction? Also, when a reaction leads to hospital admission or when it is disabling (e.g. blindness, deafness).

Adverse reactions linked to a birth defect are also considered serious irrespective of the severity of the birth problem.

JAMASOFT2017

12Slide13

What should one do in case of serious reactions? It can be very difficult to determine cause and effect of a drug and a serious reaction.

The doctor or pharmacist who is familiar with the medical history of the patient is best placed to make an assessment.

If a side effect is possibly related to the medicine you are taking, the Healthcare Professional should

report to the government authorities

and/or to the pharmaceutical company concerned.

JAMASOFT2017

13Slide14

For European medicines, the EMA collects all such reports within a central database called EudraVigilance.JAMASOFT2017

EudraVigilance

14Slide15

EudraVigilance(European Union

Drug Regulating

Authorities Pharmacovigilance)

is the European data processing network and management system for reporting and evaluation of suspected

adverse reactions

during the development of new

drugs

and for following the marketing

authorization of medicinal products in the

European Economic Area

.

JAMASOFT2017

15Slide16

EudraVigilanceThe EMA is responsible for the development, maintenance and coordination of EudraVigilance

, a

system designed for the reporting of suspected side effects.

Reports submitted to

EudraVigilance

include

suspected side effects of medicines

reported during both the pre- and post-authorization phases.

The system allows the detection of signals of suspected side effects that were previously unknown, and of new information on known side effects.

JAMASOFT2017

16Slide17

Pharmacoepidemiology relation with pharmacovigilance.

In studying Adverse Drug Reaction (ADRs) we study the case reports on an individual basis i.e. whether the adverse reaction was actually caused by the use of the drug.

Here we are dealing with a case of

subjective clinical judgment.

But in the Adverse Event (AE), we need to conduct many controlled clinical studies to evaluate and finally consider whether the adverse reaction is evolved, and/or repeated more often in certain population than in others.

JAMASOFT2017

17Slide18

The need of pharmacoepidemiology.

As an important arm for pharmacovigilance, recently many voices are raised to consider using clinical trials in the

post-marketing surveillance phase

and not only depending on non-clinical or experimental methods to study drug safety issues after marketing the drug

. 

JAMASOFT2017

18Slide19

All regulatory authoritiesare now interested

in discovering the rare and non-listed ADRs from newly launched.They encourage pharmaceutical companies to implement a pharmacovigilance reporting system to following up their launched products worldwide and report the pharmacoepidemiology impact.

JAMASOFT2017

19Slide20

Healthcare professionalse.g. Doctors and Pharmacists

have a role too, in reporting suspected side effects of medicines to government agencies or pharmaceutical companies

.

JAMASOFT2017

20Slide21

Post-marketing studies.

Post-marketing studies explore and effectively explain how other contributing factors such as other diseases and/or other drugs might modify the efficacy and safety of the drug in use also explain the

differences in drug regimen, and patients’ compliance.

JAMASOFT2017

21Slide22

Pre-marketing studies of drug effects are limited in size; they are looking after carefully selected patients under a certain known environment and experimental conditions which is completely different from patients using the drug by their own in their real living environment.

JAMASOFT2017

22Slide23

Although if no adverse drug effects reported post-marketing,it’s a positive and reassuring point for health care professionals about the safety of the drug they are prescribed to their patients.

Also its an indicator that the study conducted is fulfilling its systems on an ethical basis with a sense of responsibility towards its customers.

JAMASOFT2017

23Slide24

Pharmacoepidemilogytogether with a successfully implemented pharmacovigilance system

can

minimise, prevent

, and

improve

the use of drugs by discovering,

at the post-marketing phase

, the adverse effects at the level of general public use. This will ensure the safety and better use of drugs towards the needed efficacy

for treating illnesses.

JAMASOFT2017

24Slide25

Can patients report directly? There is nothing to stop a patient reporting via their

doctor or pharmacist.

These health care professionals can help put the information into the right medical context for further evaluation by the authorities, particularly if they suspect a serious or severe reaction.

JAMASOFT2017

25Slide26

What regulatory action can be taken? Sometimes, this action will involve warnings to the public and the medical community aimed at ensuring the safe use of a medicine and the prevention of future side effects.

In extreme situations and, when justified, medicines have been

removed from the market in order to protect public health.

This is when the balance of risks outweighs benefits of the particular medicine.

JAMASOFT2017

26Slide27

The marketing authorization holder

has the duty of continuously ensuring post-marketing surveillance of its products and must have an appropriately qualified person at his disposal. The holder must record, report and keep a database of all suspected adverse reactions brought to his attention either directly (by the reporting of a health professional) or indirectly (e.g. by the medical literature). The basis for reporting may be:

Expedited

(i.e. within 15 days from receipt) for those reactions likely to be most significant (by and large, those which are serious or unexpected)

.

Or

periodic

, in the form of a Periodic Safety Update Report (PSUR), 6-monthly for the first 2 years after

authori

z

ation

and then yearly until the quinquennial renewal of the marketing

authorization. These PSURs must include appropriate information on the exposure, in particular the volume of sales of the medicinal product concerned.

The marketing

authori

z

ation

holder may also undertake post-

authori

z

ation

studies, e.g. in order to assess more accurately the safety of its product in varied situations (such as specific sub-populations). Finally, the holder must ensure that any request from the regulatory authorities is answered fully and promptly. A number of guidelines are available for expedited reporting, PSURs and company-sponsored post-

authori

z

ation

studies.

JAMASOFT2017

27Slide28

EMA EU New Pharmacovigilance LegislationJuly

2012

Good Pharmacovigilance Practices

JAMASOFT2017

28Slide29

Good pharmacovigilance practices (GVP)

are a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU).

GVP apply to marketing-

authori

z

ation

holders, the European Medicines Agency and medicines regulatory authorities in EU Member States.

They cover medicines authorized centrally via the Agency as well as medicines

authorized

at national level.

JAMASOFT2017

29Slide30

Thanks

for

your

attention

.

JAMASOFT2017

30